- Home
- UGRO vs ONCO Comparison
UGRO vs ONCO Comparison
Compare UGRO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- ONCO
- Stock Information
- Founded
- UGRO 2014
- ONCO 2018
- Country
- UGRO United States
- ONCO United States
- Employees
- UGRO N/A
- ONCO N/A
- Industry
- UGRO Industrial Specialties
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- ONCO Health Care
- Exchange
- UGRO Nasdaq
- ONCO Nasdaq
- Market Cap
- UGRO 8.8M
- ONCO 5.8M
- IPO Year
- UGRO N/A
- ONCO 2022
- Fundamental
- Price
- UGRO $0.74
- ONCO $0.40
- Analyst Decision
- UGRO Strong Buy
- ONCO
- Analyst Count
- UGRO 2
- ONCO 0
- Target Price
- UGRO $3.13
- ONCO N/A
- AVG Volume (30 Days)
- UGRO 133.4K
- ONCO 9.9M
- Earning Date
- UGRO 03-26-2025
- ONCO 04-10-2025
- Dividend Yield
- UGRO N/A
- ONCO N/A
- EPS Growth
- UGRO N/A
- ONCO N/A
- EPS
- UGRO N/A
- ONCO N/A
- Revenue
- UGRO $59,985,133.00
- ONCO $1,870,605.00
- Revenue This Year
- UGRO $17.15
- ONCO N/A
- Revenue Next Year
- UGRO $21.76
- ONCO N/A
- P/E Ratio
- UGRO N/A
- ONCO N/A
- Revenue Growth
- UGRO 12.08
- ONCO N/A
- 52 Week Low
- UGRO $0.60
- ONCO $0.32
- 52 Week High
- UGRO $2.75
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- UGRO 39.73
- ONCO 33.18
- Support Level
- UGRO $0.66
- ONCO $0.58
- Resistance Level
- UGRO $0.79
- ONCO $0.70
- Average True Range (ATR)
- UGRO 0.10
- ONCO 0.06
- MACD
- UGRO 0.01
- ONCO -0.01
- Stochastic Oscillator
- UGRO 18.26
- ONCO 0.00
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.